Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130238 | 1.00 | SMPD1 (0.50) | SMPD1SLC6A5LPAR3LPAR1LPAR2 | |
| SCHEMBL4064805 | 1.00 | SMPD1 (0.50) | SMPD1SLC6A5LPAR3LPAR1LPAR2 | |
| SCHEMBL27542771 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL744377 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL5481597 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL27835477 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL596695 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL1044719 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL27699114 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL9026174 | 0.90 | SMPD1 (0.49) | SMPD1LPAR3LPAR1LPAR2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710927-A1 | OLEYLPHOSPHOCHOLINE IN THE TREATMENT OF LEISHMANIASIS | Oblita Therapeutics BVBA (BE) | 2026-03-18 | — | — | EP | claimed |
| US-12214081-B2 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2025-02-04 | — | — | US | claimed |
| EP-3965739-B1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2024-07-10 | — | — | EP | claimed |
| US-20220183975-A1 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2022-06-16 | — | — | US | claimed |
| EP-3965739-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | Oblita Therapeutics BVBA (BE) | 2022-03-16 | — | — | EP | claimed |
| WO-2020208230-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2020-10-15 | — | — | WO | claimed |
| EP-2680857-B1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | OBLITA THERAPEUTICS BVBA (BE) | 2019-04-24 | — | — | EP | claimed |
| EP-2642981-B1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2017-05-17 | — | — | EP | claimed |
| US-9358244-B2 | Solid dosage forms of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2016-06-07 | — | — | US | claimed |
| EP-2136816-B1 | OLEYL PHOSPHOCHOLINE | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2014-12-31 | — | — | EP | claimed |
| US-20140193493-A1 | Solid Dosage Forms of Oleyl Phosphocholine | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2014-07-10 | — | — | US | claimed |
| US-20130345177-A1 | Oleyl Phosphocholine for the Treatment of Mycosis | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-12-26 | — | — | US | claimed |
| EP-2663282-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | Dafra Pharma Research & Development BVBA (BE) | 2013-11-20 | — | — | EP | claimed |
| US-20130296277-A1 | Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-11-07 | — | — | US | claimed |
| EP-2642981-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | Dafra Pharma Research & Development BVBA (BE) | 2013-10-02 | — | — | EP | claimed |
| WO-2012119870-A1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-09-13 | — | — | WO | claimed |
| WO-2012095500-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-07-19 | — | — | WO | claimed |
| WO-2012069427-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-05-31 | — | — | WO | claimed |
| US-20100144676-A1 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-06-10 | — | — | US | claimed |
| EP-4710927-A1 | OLEYLPHOSPHOCHOLINE IN THE TREATMENT OF LEISHMANIASIS | Oblita Therapeutics BVBA (BE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4710927-A1 | OLEYLPHOSPHOCHOLINE IN THE TREATMENT OF LEISHMANIASIS | Oblita Therapeutics BVBA (BE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4132472-B1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2025-03-26 | — | — | EP | disclosed |
| EP-4132472-C0 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2025-03-26 | — | — | EP | disclosed |
| US-12214081-B2 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2025-02-04 | — | — | US | disclosed |
| US-12214081-B2 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2025-02-04 | — | — | US | disclosed |
| US-12214081-B2 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2025-02-04 | — | — | US | disclosed |
| EP-3965739-B1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3965739-C0 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3965739-B1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2024-07-10 | — | — | EP | disclosed |
| US-20230147712-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230147712-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230147712-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2023-05-11 | — | — | US | disclosed |
| EP-4132472-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | Oblita Therapeutics BVBA (BE) | 2023-02-15 | — | — | EP | disclosed |
| EP-4132472-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | Oblita Therapeutics BVBA (BE) | 2023-02-15 | — | — | EP | disclosed |
| EP-4132472-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | Oblita Therapeutics BVBA (BE) | 2023-02-15 | — | — | EP | disclosed |
| US-20220183975-A1 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2022-06-16 | — | — | US | disclosed |
| US-20220183975-A1 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2022-06-16 | — | — | US | disclosed |
| US-20220183975-A1 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2022-06-16 | — | — | US | disclosed |
| EP-3965739-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | Oblita Therapeutics BVBA (BE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3965739-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | Oblita Therapeutics BVBA (BE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3965739-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | Oblita Therapeutics BVBA (BE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2021204409-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2021-10-14 | — | — | WO | disclosed |
| WO-2021204409-A1 | OLEYL PHOSPHOCHOLINE CONTAINING GRANULATES | OBLITA THERAPEUTICS BVBA (BE) | 2021-10-14 | — | — | WO | disclosed |
| WO-2020208230-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020208230-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020208230-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020025848-A1 | ZWITTERIONIC COMPOUNDS OF 2-PHOSPHOCHOLINE CARBOXYLIC ACIDS AND THEIR USE AS CYTOTOXIC AGENTS | UNIVERSIDAD DE ALICANTE (ES) | 2020-02-06 | — | — | WO | disclosed |
| EP-2680857-B1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | OBLITA THERAPEUTICS BVBA (BE) | 2019-04-24 | — | — | EP | disclosed |
| EP-2680857-B1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | OBLITA THERAPEUTICS BVBA (BE) | 2019-04-24 | — | — | EP | disclosed |
| EP-2642981-B1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2642981-B1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-9358244-B2 | Solid dosage forms of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2016-06-07 | — | — | US | disclosed |
| US-9358244-B2 | Solid dosage forms of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2016-06-07 | — | — | US | disclosed |
| US-9358244-B2 | Solid dosage forms of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2016-06-07 | — | — | US | disclosed |
| US-9326989-B2 | Oleyl phosphocholine | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-05-03 | — | — | US | disclosed |
| US-9326989-B2 | Oleyl phosphocholine | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-05-03 | — | — | US | disclosed |
| US-9326989-B2 | Oleyl phosphocholine | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-05-03 | — | — | US | disclosed |
| WO-2015193669-A1 | DIAGNOSTIC AND THERAPEUTIC METHOD INVOLVING THE AUTOTAXIN-LYSOPHOSPHATIDIC ACID SIGNALLING PATHWAY | BABRAHAM INSTITUTE (GB) | 2015-12-23 | — | — | WO | disclosed |
| EP-2136816-B1 | OLEYL PHOSPHOCHOLINE | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140193493-A1 | Solid Dosage Forms of Oleyl Phosphocholine | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2014-07-10 | — | — | US | disclosed |
| US-20140193493-A1 | Solid Dosage Forms of Oleyl Phosphocholine | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2014-07-10 | — | — | US | disclosed |
| US-20130345177-A1 | Oleyl Phosphocholine for the Treatment of Mycosis | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-12-26 | — | — | US | disclosed |
| US-20130345177-A1 | Oleyl Phosphocholine for the Treatment of Mycosis | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-12-26 | — | — | US | disclosed |
| EP-2663282-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | Dafra Pharma Research & Development BVBA (BE) | 2013-11-20 | — | — | EP | disclosed |
| EP-2663282-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | Dafra Pharma Research & Development BVBA (BE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296277-A1 | Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296277-A1 | Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration | DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2642981-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | Dafra Pharma Research & Development BVBA (BE) | 2013-10-02 | — | — | EP | disclosed |
| EP-2642981-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | Dafra Pharma Research & Development BVBA (BE) | 2013-10-02 | — | — | EP | disclosed |
| EP-2642981-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | Dafra Pharma Research & Development BVBA (BE) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012095500-A3 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012119870-A1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012119870-A1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012119870-A1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012095500-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095500-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012069427-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069427-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069427-A1 | SOLID DOSAGE FORMS OF OLEYL PHOSPHOCHOLINE | DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA (BE) | 2012-05-31 | — | — | WO | disclosed |
| US-20100144676-A1 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144676-A1 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144676-A1 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-2136816-A2 | OLEYL PHOSPHOCHOLINE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-2136816-A2 | OLEYL PHOSPHOCHOLINE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008116641-A3 | OLEYL PHOSPHOCHOLINE | MAX PLANCK GESELLSCHAFT (DE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008116641-A3 | OLEYL PHOSPHOCHOLINE | MAX PLANCK GESELLSCHAFT (DE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008116641-A2 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116641-A2 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-10-02 | — | — | WO | disclosed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0311163-A2 | Use of site-specific modified lipolytic enzymes for the selective hydrolysis of organized lipid structures | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-04-12 | — | — | EP | disclosed |
| EP-0311163-A2 | Use of site-specific modified lipolytic enzymes for the selective hydrolysis of organized lipid structures | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-04-12 | — | — | EP | disclosed |